Public Health Groups Close Ranks Against Tobacco Industry

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WASHINGTON-The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

WASHINGTON—The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

The ACS has joined forces with 10 other major national public health organizations to garner grassroots support to help move the proposal through Congress quickly before momentum fades.

ASCO’s Position

The American Society of Clinical Oncology (ASCO), in a statement issued a few days before the President’s address, also called for major changes to strengthen the proposed settlement.

Of special concern is the focus of the $25 billion research fund included in the tobacco settlement. The Society wants to see the fund sponsor a balanced portfolio of basic and clinical research on tobacco-related cancers and other diseases, and install a rigorous, science-based, peer-reviewed system for making grants.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content